Clinical trial
A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral…
NCT02653976 · Solasia Pharma K.K., Industry · Completed
Key facts
| NCT number | NCT02653976 |
|---|---|
| Title | A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) |
| Official title | Asian Multinational Phase 2 Study of SP-02L (Darinaparsin for Injection) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) |
| Lead sponsor | Solasia Pharma K.K., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Peripheral T-Cell Lymphoma |
| Intervention type | Drug |
| Interventions | SP-02L (darinaparsin for injection) |
| Enrollment | 67 |
| Start date | Mar 25, 2016 |
| Primary completion | Oct 11, 2020 |
| Completion | Jun 17, 2021 |
| First posted | Jan 13, 2016 |
| Last update posted | Jan 26, 2024 |
| Countries | Hong Kong, Japan, South Korea, Taiwan |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: